The terminal membrane attack complex (MAC) is formed by five complement protein factors: C5b, C6, C7, C8, and C9.
This ordered assembly, often denoted C5b-9, creates a pore in target cell membranes. For diagnostic developers, knowing this exact composition is the starting point for building assays that measure terminal pathway activity without mistaking partial complexes for the fully formed, lytic MAC.
The MAC’s composition as C5b, C6, C7, C8, and multiple C9 molecules defines both its lytic function and the analyte targets for immunodiagnostics. Accurate assay design demands high-purity, stabilized proteins and highly specific antibodies that distinguish the assembled MAC from its individual precursors and non-functional activation byproducts.
The Molecular Assembly of the MAC
Initiation by C5b
The process begins when C5 convertase cleaves C5.
This releases the potent anaphylatoxin C5a, while C5b remains anchored to the target surface.
C5b’s labile binding site immediately requires C6 to prevent inactivation.
Sequential Recruitment of C6, C7, and C8
C6 binds to C5b, forming a stable C5b6 intermediate.
C7 then attaches, creating a hydrophobic C5b67 complex that inserts directly into the lipid bilayer.
C8 binding stabilizes the structure and initiates membrane penetration by its α‑chain.
Polymerization of C9 into the Pore
The C5b-8 complex acts as a receptor for C9 molecules.
12 to 15 C9 proteins polymerize into a ring, forming a transmembrane β‑barrel pore.
This pore allows uncontrolled ion and water influx, causing osmotic swelling and cell lysis.
Why MAC Composition Matters for Immunodiagnostic Design
Differentiating Activation Products from Intact Complexes
The fully assembled MAC (C5b-9) is the functional endpoint; precursor fragments like C5a or unbound C9 are not.
Diagnostic assays must use monoclonal antibodies that exclusively recognize a neoepitope on the polymerized C9 ring or the assembled complex.
Cross-reactivity with soluble components would falsely elevate results and obscure a patient’s true complement status.
Ensuring Functional Integrity in Hemolytic Assays
Classical tests like CH50 and AH50 measure the MAC’s ability to lyse antibody‑coated erythrocytes.
Any loss of function in a single component (C5 through C9) abolishes lysis, making these assays sensitive to total terminal pathway activity.
Therefore, developers rely on complement‑depleted sera and purified, active components to validate that only the terminal pathway is being measured.
Raw Material Selection: Proteins, Antibodies, and Controls
Building robust immunoassays requires stabilized, high‑purity C5b, C6, C7, C8, and C9 antigens.
These raw materials must retain their native conformation to generate reliable calibration curves and control lots.
Equally critical are lot‑consistent detection antibodies that maintain specificity across production batches, minimizing variability.
Understanding the Trade-offs in Assay Development
Risk of Non-Specific Activation
Handling purified complement proteins can trigger spontaneous hydrolysis or aggregation that mimics genuine MAC formation.
Even minor contamination with activated fragments can lead to background signals that erode assay sensitivity.
Manufacturers must incorporate sterile, endotoxin‑free processing and optimized storage buffers to keep proteins in their unactivated state.
Lot-to-Lot Variability and Standardization
Antibody affinity and antigen stability vary between production runs, directly impacting assay lot‑to‑lot consistency.
Diagnostic developers must implement rigorous quality controls—such as defined cut‑off calibrators and functional hemolytic titers—to normalize output across batches.
Without this standardization, patient results lose comparability, undermining clinical utility.
Making the Right Choice for Your Assay Goal
The ideal raw material and antibody panel depends entirely on what you need to measure.
- If your primary focus is total terminal pathway function: Use a hemolytic assay (CH50) with preserved whole‑serum samples; prioritize the full cascade activity over single‑component quantification.
- If your primary focus is specific MAC quantification in patient fluids: Select a neoepitope‑specific monoclonal antibody that detects only the polymerized C5b-9 complex and not free C9 or precursor C5b‑8.
- If your primary focus is therapeutic antibody screening for CDC: Validate each complement lot with functional MAC formation on target cells, and pair with high‑activity C5-C9 components to ensure reproducible cytotoxicity readouts.
Selecting proteins and antibodies that faithfully mirror the MAC’s exact molecular assembly transforms a simple binding signal into a trusted diagnostic endpoint.
Summary Table:
| MAC Component | Assembly Role | Immunodiagnostic Significance |
|---|---|---|
| C5b | Initiates complex assembly after C5 cleavage | Anchors to target surface; requires C6 to prevent rapid inactivation |
| C6 & C7 | Form the hydrophobic C5b67 intermediate | Enables insertion directly into the target lipid bilayer |
| C8 | Binds C5b67 and penetrates membrane | Recruits C9 and initiates membrane penetration |
| C9 | Polymerizes (12–15 molecules) into β-barrel pore | Primary target for neoepitope antibodies to measure fully assembled MAC |
Building high-performance complement assays requires lot-consistent, stable antigens and specific antibodies that distinguish intact complexes from inactive precursors. CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—supporting your development every step of the way, from concept to clinic.
Ready to elevate your assay reliability? Contact CamelBio today to source high-purity complement proteins and specialized reagents tailored to your diagnostic needs.